AIM:ONC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. More Details


Snowflake Analysis

High growth potential with weak fundamentals.

Share Price & News

How has Oncimmune Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ONC is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ONC's weekly volatility has decreased from 13% to 6% over the past year.


Market Performance


7 Day Return

0%

ONC

4.3%

GB Biotechs

-0.3%

GB Market


1 Year Return

406.8%

ONC

47.9%

GB Biotechs

-7.9%

GB Market

Return vs Industry: ONC exceeded the UK Biotechs industry which returned 47.9% over the past year.

Return vs Market: ONC exceeded the UK Market which returned -7.9% over the past year.


Shareholder returns

ONCIndustryMarket
7 Day0%4.3%-0.3%
30 Day11.9%17.6%5.4%
90 Day5.6%14.8%15.7%
1 Year406.8%406.8%48.6%47.9%-4.1%-7.9%
3 Year45.3%45.3%25.0%23.3%4.2%-8.5%
5 Yearn/a53.5%50.6%45.0%12.1%

Long-Term Price Volatility Vs. Market

How volatile is Oncimmune Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oncimmune Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Oncimmune Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Oncimmune Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Oncimmune Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

37.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ONC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: ONC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ONC's is expected to become profitable in the next 3 years.

Revenue vs Market: ONC's revenue (34% per year) is forecast to grow faster than the UK market (6.5% per year).

High Growth Revenue: ONC's revenue (34% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ONC is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Oncimmune Holdings performed over the past 5 years?

-9.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ONC is currently unprofitable.

Growing Profit Margin: ONC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ONC is unprofitable, and losses have increased over the past 5 years at a rate of 9.6% per year.

Accelerating Growth: Unable to compare ONC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: ONC's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Oncimmune Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: ONC has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ONC has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ONC has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ONC's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ONC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ONC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Oncimmune Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ONC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ONC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ONC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ONC's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Adam Hill (40 yo)

2.33yrs

Tenure

UK£385,000

Compensation

Dr. Adam Mark Hill, MB, PhD, has been the Chief Executive Officer at Oncimmune Holdings Plc since September 2018. Dr. Mark also served as Director at Oncimmune Holdings Plc. He served as Chief Medical Offi...


CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD525.19K) is about average for companies of similar size in the UK market ($USD581.40K).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Adam Hill
CEO & Director2.33yrsUK£385.00k5.56%
£ 6.6m
Matthew Hall
Chief Financial Officer2.08yrsno data0.019%
£ 22.4k
Tariq Sethi
Chief Scientific Officer1.25yrsno datano data
Cléa Rosenfeld
Head of Investor Relations1.5yrsno datano data
Ron Kirschner
General Counsel & Company Secretary0.75yrno data0.0026%
£ 3.1k
James Jett
Chief Medical Officer of US5yrsno datano data
Maarten Brusse
Chief Commercial Officer of Asia4.33yrsno datano data
Shane Smith
Senior Vice President of Market Access & Reimbursement Oncimmune (Usa)3.75yrsno datano data
Matthew Luttrell
Chief Commercial Officer1.25yrsno datano data
Andrew Millet
Executive2.08yrsUK£215.36kno data
Daniel Calvo
Senior Advisor4.83yrsno datano data

2.1yrs

Average Tenure

Experienced Management: ONC's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adam Hill
CEO & Director2.33yrsUK£385.00k5.56%
£ 6.6m
Timothy Bunting
Non-Executive Directorno datano data4.64%
£ 5.5m
Andrew Unitt
Independent Non Executive Director7yrsUK£18.00kno data
Annalisa Jenkins
Senior Independent Non-Executive Directorno dataUK£36.00kno data
Meinhard Schmidt
Non-Executive Chairman5.33yrsUK£75.00k0.049%
£ 58.1k
Parag Mallick
Member of Scientific Board1.75yrsno datano data
Cheung To
Non-Executive Director2.33yrsno datano data
Richard Roope
Member of Scientific Board2.08yrsno datano data
Nora Pashayan
Member of Scientific Board2.08yrsno datano data
Ola Winqvist
Member of Scientific Board2.08yrsno datano data

2.1yrs

Average Tenure

56yo

Average Age

Experienced Board: ONC's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ONC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Oncimmune Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oncimmune Holdings plc
  • Ticker: ONC
  • Exchange: AIM
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£119.367m
  • Shares outstanding: 63.66m
  • Website: https://www.oncimmune.com

Number of Employees


Location

  • Oncimmune Holdings plc
  • D6 Building
  • 1 Thane Road
  • Nottingham
  • Nottinghamshire
  • NG90 6BH
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ONCAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMay 2016
OCYBST (Boerse-Stuttgart)YesOrdinary SharesDEEURMay 2016
OCMM.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 2016

Biography

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a blood test for ear...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/20 18:38
End of Day Share Price2021/01/20 00:00
Earnings2020/05/31
Annual Earnings2020/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.